The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Overview of PDEs and Their Regulation
Omori, K., & Kotera, J. (2007) · Circulation Research · doi:10.1161/01.res.0000256354.95791.f1 · Cited by 796
HOUSLAY, M. D., & ADAMS, D. R. (2003) · Biochemical Journal · doi:10.1042/bj20021698 · Cited by 763
Toward a molecular definition of long-term memory storage
Bailey, C. H., Bartsch, D., & Kandel, E. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13445 · Cited by 691
DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling
Millar, J. K., Pickard, B. S., Mackie, S., James, R., Christie, S., Buchanan, S. R., Malloy, M. P., Chubb, J. E., Huston, E., Baillie, G. S., et al. (2005) · Science · doi:10.1126/science.1112915 · Cited by 648 · cited 1×
“7 ) also explains recent peptide-array, yeast-two-hybrid and immunoprecipitation studies demonstrating that partner proteins can decrease PDE4 activit”
BackgroundKeynote review: Phosphodiesterase-4 as a therapeutic target
Houslay, M. D., Schafer, P., & Zhang, K. Y. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03622-6 · Cited by 635
Lehnart, S. E., Wehrens, X. H. T., Reiken, S., Warrier, S., Belevych, A. E., Harvey, R. D., Richter, W., Jin, S.-L. C., Conti, M., & Marks, A. R. (2005) · Cell · doi:10.1016/j.cell.2005.07.030 · Cited by 517
RAR and RXR modulation in cancer and metabolic disease
Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R., & Gronemeyer, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2397 · Cited by 517
Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases
Card, G. L., England, B. P., Suzuki, Y., Fong, D., Powell, B., Lee, B., Luu, C., Tabrizizad, M., Gillette, S., Ibrahim, P. N., et al. (2004) · Structure · doi:10.1016/j.str.2004.10.004 · Cited by 432
Sette, C., & Conti, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.28.16526 · Cited by 409
Cited by
Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases
Park, S.-J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H., Rehmann, H., Taussig, R., Brown, A. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.017 · Cited by 1,349
Self-citationMillan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Advances in targeting cyclic nucleotide phosphodiesterases
Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J., & Manganiello, V. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4228 · Cited by 776
Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions
Francis, S. H., Blount, M. A., & Corbin, J. D. (2011) · Physiological Reviews · doi:10.1152/physrev.00030.2010 · Cited by 639
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Li, H., Zuo, J., & Tang, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01048 · Cited by 580
Keravis, T., & Lugnier, C. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01729.x · Cited by 385
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
Baillie, G. S., Tejeda, G. S., & Kelly, M. P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0033-4 · Cited by 339
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Schmidtke, P., & Barril, X. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100574m · Cited by 331
Clinical and Molecular Genetics of the Phosphodiesterases (PDEs)
Azevedo, M. F., Faucz, F. R., Bimpaki, E., Horvath, A., Levy, I., de Alexandre, R. B., Ahmad, F., Manganiello, V., & Stratakis, C. A. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1053 · Cited by 325
Hatzelmann, A., Morcillo, E. J., Lungarella, G., Adnot, S., Sanjar, S., Beume, R., Schudt, C., & Tenor, H. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.03.011 · Cited by 320
The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases
Raker, V. K., Becker, C., & Steinbrink, K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00123 · Cited by 319
Interfacial inhibitors: targeting macromolecular complexes
Pommier, Y., & Marchand, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3404 · Cited by 259
Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease
García-Osta, A., Cuadrado-Tejedor, M., García-Barroso, C., Oyarzábal, J., & Franco, R. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn3000907 · Cited by 259
Emerging Role of cAMP/AMPK Signaling
Aslam, M., & Ladilov, Y. (2022) · Cells · doi:10.3390/cells11020308 · Cited by 241
“Indeed, several reports have shown positive health effects of PDE4 inhibitors in animal models, including improved memory [75] or protection against diet-induced obesity and glucose intolerance [60].”
BackgroundBerry-Kravis, E. M., Harnett, M. D., Reines, S. A., Reese, M. A., Ethridge, L. E., Outterson, A. H., Michalak, C., Furman, J., & Gurney, M. E. (2021) · Nature Medicine · doi:10.1038/s41591-021-01321-w · Cited by 131
Self-citationDISC1: Structure, Function, and Therapeutic Potential for Major Mental Illness
Soares, D. C., Carlyle, B. C., Bradshaw, N. J., & Porteous, D. J. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200062k · Cited by 129
Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer's Disease
Gurney, M. E., D'Amato, E. C., & Burgin, A. B. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0309-7 · Cited by 121
Self-citationMolecular glues and bifunctional compounds: Therapeutic modalities based on induced proximity
Schreiber, S. L. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.05.004 · Cited by 112
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics
de Waal, L., Lewis, T. A., Rees, M. G., Tsherniak, A., Wu, X., Choi, P. S., Gechijian, L., Hartigan, C., Faloon, P. W., Hickey, M. J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1984 · Cited by 96
Self-citationThe role of ventral striatal cAMP signaling in stress-induced behaviors
Plattner, F., Hayashi, K., Hernández, A., Benavides, D. R., Tassin, T. C., Tan, C., Day, J., Fina, M. W., Yuen, E. Y., Yan, Z., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4066 · Cited by 94
Wang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92
Gurney, M. E., Cogram, P., Deacon, R. M., Rex, C., & Tranfaglia, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15028-x · Cited by 69
Self-citationMacKenzie, K. F., Wallace, D. A., Hill, E. V., Anthony, D. F., Henderson, D. J. P., Houslay, D. M., Arthur, J. S. C., Baillie, G. S., & Houslay, M. D. (2011) · Biochemical Journal · doi:10.1042/bj20101184 · Cited by 65
Liu, J., Liu, L., Zheng, L., Feng, K.-W., Wang, H.-T., Xu, J.-P., & Zhou, Z.-Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114503 · Cited by 28
Roflumilast: A potential drug for the treatment of cognitive impairment?
Sugin, L. J. S., Murugesan, A., Bindu, M., & Sunil, K. N. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135281 · Cited by 24
Metadata
- Authors
- Burgin, A. B., Magnusson, O. T., Singh, J., Witte, P., Staker, B. L., Bjornsson, J. M., Thorsteinsdottir, M., Hrafnsdottir, S., Hagen, T., Kiselyov, A. S., Stewart, L. J., & Gurney, M. E.
- Venue
- Nature Biotechnology
- Published
- 2010-01
- Volume
- 28
- Issue
- 1
- Pages
- 63-70
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1997277329
- Cited by
- 397
- References
- 44
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.